Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Are plasma biomarkers of immune activation predictive of HIV progression: a longitudinal comparison and analyses in HIV-1 and HIV-2 infections?

Nyamweya S, Townend J, Zaman A, Steele SJ, Jeffries D, Rowland-Jones S, Whittle H, Flanagan KL, Jaye A.

PLoS One. 2012;7(9):e44411. doi: 10.1371/journal.pone.0044411. Epub 2012 Sep 10.

2.

Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau.

Jaffar S, Van der Loeff MS, Eugen-Olsen J, Vincent T, Sarje-Njie R, Ngom P, Meyer AM, Berry N, Aaby P, Whittle H.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):560-4.

PMID:
15989461
3.

Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.

Zangerle R, Steinhuber S, Sarcletti M, Dierich MP, Wachter H, Fuchs D, Möst J.

Int Arch Allergy Immunol. 1998 Jul;116(3):228-39.

PMID:
9693271
4.

Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.

Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J.

Clin Infect Dis. 2005 Mar 15;40(6):853-8. Epub 2005 Feb 18.

PMID:
15736019
5.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F; French ANRS HIV-2 CO5 Cohort.

Clin Infect Dis. 2012 Nov 15;55(10):1417-25. doi: 10.1093/cid/cis708. Epub 2012 Aug 20.

PMID:
22911639
6.

Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease.

Kamat A, Ravi V, Desai A, Satishchandra P, Satish KS, Kumar M.

J Neurovirol. 2009 Jan;15(1):25-35. doi: 10.1080/13550280802338652. Epub 2008 Nov 22.

PMID:
19031329
7.

Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.

Liovat AS, Rey-Cuillé MA, Lécuroux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barré-Sinoussi F, Lebon P, Meyer L, Sinet M, Müller-Trutwin M.

PLoS One. 2012;7(10):e46143. doi: 10.1371/journal.pone.0046143. Epub 2012 Oct 2.

8.

Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.

Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, Giorgi JV, Detels R.

AIDS. 1998 Sep 10;12(13):1581-90.

PMID:
9764776
9.
10.

High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.

Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):23-31.

PMID:
15851910
11.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

12.

Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection.

Zangerle R, Fuchs D, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Dierich MP, Möst J.

Clin Immunol Immunopathol. 1994 Sep;72(3):328-34.

PMID:
7914841
13.

Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.

De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, Chiodi F.

Clin Exp Immunol. 2002 Mar;127(3):486-94. Erratum in: Clin Exp Immunol. 2003 Oct;134(1):167. D Fuchs [corrected to Fuchs D].

14.

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection.

Suh J, Sinclair E, Peterson J, Lee E, Kyriakides TC, Li FY, Hagberg L, Fuchs D, Price RW, Gisslen M, Spudich S.

J Neuroinflammation. 2014 Dec 3;11:199. doi: 10.1186/s12974-014-0199-y.

15.

Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression.

Shi M, Taylor JM, Fahey JL, Hoover DR, Muñoz A, Kingsley LA.

J Clin Immunol. 1997 Jan;17(1):43-52.

PMID:
9049785
16.

Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.

Skogmar S, Schön T, Balcha TT, Sturegård E, Jansson M, Björkman P.

PLoS One. 2015 Dec 2;10(12):e0144292. doi: 10.1371/journal.pone.0144292. eCollection 2015.

17.

Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression.

Graham SM, Rajwans N, Jaoko W, Estambale BB, McClelland RS, Overbaugh J, Liles WC.

AIDS. 2013 Jul 17;27(11):1803-13. doi: 10.1097/QAD.0b013e328360e9fb.

18.

Surrogate markers of disease progression in HIV-infected children in Rio de Janeiro, Brazil.

Ortigão-de-Sampaio MB, Abreu TF, Linhares-de-Carvalho MI, Ponce de Leon A, Castello-Branco LR.

J Trop Pediatr. 1999 Oct;45(5):299-302.

PMID:
10584474
20.

Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.

Whittle H, Egboga A, Todd J, Corrah T, Wilkins A, Demba E, Morgan G, Rolfe M, Berry N, Tedder R.

AIDS. 1992 Jul;6(7):685-9.

PMID:
1354448

Supplemental Content

Support Center